Anti-CR2 (THB-5)-Mc-MMAF ADC

  • 1.00 Dollar US$
  • Published date: November 29, 2017
    • Shirley, New York, United States

This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a Mc linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation. Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-CR2 (THB-5)-MCC-DM1 ADC

    Anti-CR2 (THB-5)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-CR2 (THB-5)-SPP-DM1 ADC

    Anti-CR2 (THB-5)-SPP-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-CR2 (clone HB135)-MCC-DM1 ADC

    Anti-CR2 (clone HB135)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (clone HB135) conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...